Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03462680 · ClinicalTrials.gov registry record · NA

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

A NA study of Parkinson's Disease, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
47
Enrollment target
1
Study location

NCT03462680 is a NA study of Parkinson's Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 47 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03462680, a NA study of Parkinson's Disease, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency . The purposes of this study are to (1) examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 6 months of vitamin B3 supplements may reduce the inflammation and/or improve symptoms.

Conditions Studied

Interventions

  • OTHER placebo
  • DIETARY_SUPPLEMENT niacin

Study Locations (1)

Georgia

  • Charlie Norwood VA Medical Center, Augusta, GA - Augusta

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2016-09-28
Est. Completion 2020-04-23
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03462680

The ClinicalTrials.gov registry entry for NCT03462680 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (93% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT03462680 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03462680 about?

NCT03462680 is a clinical study titled "GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures". Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The investigators also found that individuals with PD have a chronic niacin deficiency . The purposes o...

What is the current status of trial NCT03462680?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2016-09-28. Estimated completion is 2020-04-23.

What conditions does trial NCT03462680 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT03462680?

The interventions under investigation include: placebo (OTHER), niacin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03462680?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03462680 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.